Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

Axxam spinout Libra is targeting autophagy and toxic protein production pathways common to multiple neurodegenerative disorders, starting with ALS.

Libra Therapeutics Inc. emerged from stealth Wednesday with a $29 million series A co-led by Boehringer Ingelheim Venture Fund, Epidarex Capital and Santé Ventures and a trio of preclinical programs from Axxam S.p.A., which provides CRO services in addition to its internal drug discovery work. ...